{"result": {"id": "0249e41d-5ed4-4f87-ac17-36fe29186a11", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SPC<|>ORGANIZATION<|>SPC refers to Single Pill Combination, a method of combining different antihypertensive drugs into a single pill for ease of use and improved adherence to treatment)\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI stands for Angiotensin-Converting Enzyme Inhibitor, a type of antihypertensive drug)\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB stands for Angiotensin Receptor Blocker, a type of antihypertensive drug)\n##\n(\"entity\"<|>ARNI<|>ORGANIZATION<|>ARNI stands for Angiotensin Receptor Neprilysin Inhibitor, a type of antihypertensive drug)\n##\n(\"entity\"<|>CCB<|>ORGANIZATION<|>CCB stands for Calcium Channel Blocker, a type of antihypertensive drug)\n##\n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>β受体阻滞剂 is a type of antihypertensive drug that blocks beta receptors)\n##\n(\"entity\"<|>利尿剂<|>ORGANIZATION<|>利尿剂 is a type of antihypertensive drug that promotes diuresis)\n##\n(\"entity\"<|>复方利血平<|>ORGANIZATION<|>复方利血平 is a traditional Chinese antihypertensive combination drug)\n##\n(\"entity\"<|>复方利血平氨苯蝶啶片<|>ORGANIZATION<|>复方利血平氨苯蝶啶片 is a traditional Chinese antihypertensive combination drug)\n##\n(\"entity\"<|>珍菊降压片<|>ORGANIZATION<|>珍菊降压片 is a traditional Chinese antihypertensive combination drug)\n##\n(\"relationship\"<|>SPC<|>ACEI<|>SPC can include ACEI as one of its components<|>5)\n##\n(\"relationship\"<|>SPC<|>ARB<|>SPC can include ARB as one of its components<|>5)\n##\n(\"relationship\"<|>SPC<|>ARNI<|>SPC can include ARNI as one of its components<|>5)\n##\n(\"relationship\"<|>SPC<|>CCB<|>SPC can include CCB as one of its components<|>5)\n##\n(\"relationship\"<|>SPC<|>β受体阻滞剂<|>SPC can include β受体阻滞剂 as one of its components<|>5)\n##\n(\"relationship\"<|>SPC<|>利尿剂<|>SPC can include 利尿剂 as one of its components<|>5)\n##\n(\"relationship\"<|>复方利血平<|>复方利血平氨苯蝶啶片<|>Both are traditional Chinese antihypertensive combination drugs<|>3)\n##\n(\"relationship\"<|>复方利血平<|>珍菊降压片<|>Both are traditional Chinese antihypertensive combination drugs<|>3)\n##\n(\"relationship\"<|>复方利血平氨苯蝶啶片<|>珍菊降压片<|>Both are traditional Chinese antihypertensive combination drugs<|>3)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558632, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 713, "prompt_tokens": 2474, "total_tokens": 3187, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 682}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �制药;ARB为血管紧张素受体阻滞药;ARNI为血管紧张素受体脑啡肽酶抑制剂。\n\n\n　　　(5)SPC:是联合降压治疗有效的实现方式 。通常 由不同作用机制的两种或两种以上的降压药组成 。与 随机组方的联合降压治疗相比 ,其优点是使用方便 ,可 改善治疗依从性与降压疗效[236,299] 。应用时注意其相 应组分的禁忌证和可能的不良反应。\n　　新型的 SPC:一般由不同作用机制的 2种或 3种 降压药组成 ,多数每天口服 1次 ,使用方便 ,可改善依 从性 。 目前 ,我国上市的新型的单片复方制剂主要包 括 :ACEI+噻嗪类利尿剂 ,ARB+噻嗪类利尿剂;二氢\n\n\n　吡啶类 CCB+ARB,二氢吡啶类 CCB+ACEI,二氢吡 啶类 CCB+β受体阻滞剂 ,噻嗪类利尿剂 +保钾利尿 剂等。\n　　　我国传统的 SPC: 包括复方利血平(复方降压 片) 、复方利血平氨苯蝶啶片、珍菊降压片等 , 以当时常 用的利血平、氢氯噻嗪、盐酸双肼屈嗪或可乐定等为主 要成分 。此类复方制剂目前仍较广泛使用 ,尤其是长 效的复方利血平氨苯蝶啶片。\n选择单药或联合治疗的流程图见图 5。\n\n\n　　　　　　\n　　注 :A为血管紧张素转换酶抑制药(ACEI)或血管紧张素受体阻滞药(ARB)或血管紧张素受体脑啡肽酶抑制剂(ARNI);B为 β受体阻滞剂;C为 钙通道阻滞药;D为利尿剂;F2为 2种药物的单片复方制剂;F3为 3种药物的单片复方制剂。\n图 5  选择单药或联合治疗的流程图\n\n\n　5.2.2.5   降压药的不良反应    多数高血压患者需要 终生降压治疗 , 因而应尽量减少降压治疗过程的不良 反应 。服药时特别是早期有些不良反应 ,如乏力、跌倒 及骨折增加等 。 目前 ,降压药一般不良反应较少 ,但临 床处方时 ,除了考虑药物作用外 ,也要考虑药物不良反 应 ,特别是应根据患者具体情况 ,避免禁忌证 。不同种 类降压药不良反应不同[300]  ,具体各类降压药不良反\n\n\n应参见表 19。降压药不良反应多与剂量相关 ,如噻嗪 类利尿剂的低血钾、CCB的脚踝部水肿等均与剂量相 关[301] 。\n　5.2.2.6  降压药物治疗的卫生经济学    在高血压防 治领域 ,如何有效地配置和利用有限的卫生资源 ,使之 最大限度地满足居民对高血压防控服务的需求 , 以达 到提高防控服务社会效益和经济效益的目的 ,这是卫\n\n\n\n生经济学所要解决的基本问题。\n　　　长期以来 ,我国在高血压防治卫\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_93a08c29b328dc29294b4cf5f0a092a9f9522747409b42341c93e841600e76ec_v2"}